Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

R&D Pipeline

Potential break-throughs in the making

R&D Pipeline

Potential break-throughs in the making

Asset / Program

MoA

Discovery

Preclinical

Phase 1

Phase 2

Phase 3

Oncology

Vodobatinib
(SCO-088)

BCR-ABL
Inhibitor

Refractory CML

SBO-154

Anti-MUC-1 ADC

Multiple Tumors

Immunology

Vibozilimod
(SCD-044)

Selective
S1PR1 Agonist

Psoriasis
Atopic Dermatitis

SCD-153

Undisclosed

Alopecia Areata

Vodobatinib (SCO-088)

Phase 2

BCR-ABL Inhibitor for Refractory CML

SBO-154

Preclinical

Anti-MUC-1 ADC for Multiple Tumors

Vibozilimod (SCD-044)

Phase 2

Selective S1PR1 Agonist for Psoriasis

Vibozilimod (SCD-044)

Phase 2

Selective S1PR1 Agonist for Atopic Dermatitis

SCD-153

Phase 1

Undisclosed for Alopecia Areata
  • Oncology
  • Immunology
Copyright @ 2024. All Rights Reserved.
Follow Us :
Linkedin